EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：81
|
作者：
Ke, E-E [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期
关键词：
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;
D O I：
10.1016/j.tips.2016.09.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
引用
收藏
页码：887 / 903
页数：17
相关论文
共 50 条
  • [1] The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Zhou, Fei
    Guo, Haoyue
    Xia, Yang
    Le, Xiuning
    Tan, Daniel S. W.
    Ramalingam, Suresh S.
    Zhou, Caicun
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (02) : 95 - 116
  • [2] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [3] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
    Boussageon, Maxime
    Swalduz, Aurelie
    Perol, Maurice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
  • [4] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [5] AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients
    Remon, Jordi
    Planchard, David
    FUTURE ONCOLOGY, 2015, 11 (22) : 3069 - 3081
  • [6] Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
    Fan, Y.
    Yu, X.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2228
  • [7] Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
    Pao, William
    Chmielecki, Juliann
    NATURE REVIEWS CANCER, 2010, 10 (11) : 760 - 774
  • [8] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [9] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
12345